{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:31:05Z","timestamp":1792024265207,"version":"4.4.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08708"],"award-info":[{"award-number":["19K08708"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08913"],"award-info":[{"award-number":["20K08913"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08313"],"award-info":[{"award-number":["22K08313"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Possible associations of chronic kidney disease (CKD) with fatty liver (FL) and nonalcoholic fatty liver disease (NAFLD) have recently been focused on. Metabolic dysfunction\u2013associated fatty liver disease (MAFLD), defined as FL with overweight\/obesity, type 2 diabetes mellitus or metabolic abnormalities, has been proposed as a new feature of chronic liver disease. However, the relationship between MAFLD and new onset of CKD has not been fully addressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated the associations of FL, NAFLD and MAFLD with the development of CKD, defined as an estimated glomerular filtration rate (eGFR) &amp;lt;60\u00a0mL\/min\/1.73 m2 or positive for urinary protein, over a 10-year period in 28\u2009890 Japanese subjects who received annual health examinations. After exclusion of subjects with no data for abdominal ultrasonography and subjects with CKD at baseline, a total of 13\u2009159 subjects (men 8581, women 4578; mean age 48 years) were recruited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of FL, NAFLD and MAFLD was 34.6% (men 45.1%, women 15.1%), 32.8% (men 42.7%, women 14.5%) and 32.3% (men 42.4%, women 13.4%), respectively. During the 10-year follow-up period, 2163 subjects (men 1475, women 688) had new onset of CKD. Multivariable Cox proportional hazards model analyses showed that MAFLD [hazard ratio 1.12 (95% confidence interval 1.02\u20131.26); P\u00a0=\u00a0.027] but not FL or NAFLD was an independent risk factor for new onset of CKD after adjustment of age, sex, eGFR, current smoking habit, ischemic heart disease, diabetes mellitus, overweight\/obesity, hypertension and dyslipidemia. The addition of MAFLD [continuous net reclassification improvement (NRI) 0.154, integrated discrimination improvement (IDI) 0.0024] to traditional risk factors without metabolic abnormalities significantly improved the discriminatory capacity better than did the addition of FL (NRI 0.138, IDI 0.0018) or NAFLD (NRI 0.132, IDI 0.0017).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MAFLD is modestly and independently associated with new onset of CKD and predicts the risk for development of CKD better than FL or NAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfac188","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T12:23:02Z","timestamp":1653481382000},"page":"700-711","source":"Crossref","is-referenced-by-count":56,"title":["Metabolic dysfunction\u2013associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6575-9996","authenticated-orcid":false,"given":"Marenao","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine , Sapporo , Japan"},{"name":"Tanaka Medical Clinic , Yoichi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine , Sapporo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine , Sapporo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukimura","family":"Higashiura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine , Sapporo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine , Sapporo , Japan"},{"name":"Department of Public Health, Sapporo Medical University School of Medicine , Sapporo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagisa","family":"Hanawa","sequence":"additional","affiliation":[{"name":"Department of Health Checkup and Promotion, Keijinkai Maruyama Clinic , Sapporo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-3541","authenticated-orcid":false,"given":"Masato","family":"Furuhashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine , Sapporo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CEG.S226130","article-title":"Nonalcoholic fatty liver disease and chronic kidney disease: a review of links and risks","volume":"14","author":"Cheung","year":"2021","journal-title":"Clin Exp Gastroenterol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis","year":"2010","journal-title":"Lancet"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2012.16817","article-title":"Age and association of kidney measures with mortality and end-stage renal disease","volume":"308","author":"Hallan","year":"2012","journal-title":"JAMA"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-143-10-200511150-00009","article-title":"The metabolic syndrome as a predictor of nonalcoholic fatty liver disease","volume":"143","author":"Hamaguchi","year":"2005","journal-title":"Ann Intern Med"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1440-1746.2007.05042.x","article-title":"How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?","volume":"22","author":"Amarapurkar","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace","volume":"56","author":"Baffy","year":"2012","journal-title":"J Hepatol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1507\/endocrj.EJ21-0563","article-title":"Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population","volume":"69","author":"Takahashi","year":"2022","journal-title":"Endocr J"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1038\/s41598-021-88025-w","article-title":"Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects","volume":"11","author":"Takahashi","year":"2021","journal-title":"Sci Rep"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"e021430","DOI":"10.1161\/JAHA.121.021430","article-title":"Elevated fatty liver index is independently associated with new onset of hypertension during a 10-year period in both male and female subjects","volume":"10","author":"Higashiura","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"12830","DOI":"10.1038\/s41598-021-92292-y","article-title":"High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects","volume":"11","author":"Higashiura","year":"2021","journal-title":"Sci Rep"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.13790","article-title":"High fatty liver index is an independent predictor of ischemic heart disease during a 10-year period in a Japanese population","author":"Mori","year":"2022","journal-title":"Hepatol Res"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12876-021-01782-w","article-title":"Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1016\/j.cgh.2021.01.030","article-title":"Trends in the prevalence of metabolic dysfunction-associated fatty liver disease in the United States, 2011\u20132018","volume":"20","author":"Wong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/hepr.13685","article-title":"MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach","volume":"51","author":"Tsutsumi","year":"2021","journal-title":"Hepatol Res"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","article-title":"Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan","volume":"56","author":"Yoneda","year":"2021","journal-title":"J Gastroenterol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"11629","DOI":"10.3390\/ijms222111629","article-title":"Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases","volume":"22","author":"Gutierrez-Cuevas","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2147\/DMSO.S292926","article-title":"Association between metabolic associated fatty liver disease and chronic kidney disease: a cross-sectional study from NHANES 2017-2018","volume":"14","author":"Deng","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/jdi.13678","article-title":"Metabolic associated fatty liver disease is a risk factor for chronic kidney disease","volume":"13","author":"Hashimoto","year":"2022","journal-title":"J Diabetes Investig"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc17-S005","article-title":"Classification and diagnosis of diabetes","volume":"40","author":"American Diabetes Association. 2","year":"2017","journal-title":"Diabetes Care"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1111\/j.1572-0241.2007.01526.x","article-title":"The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation","volume":"102","author":"Hamaguchi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2019.17379","article-title":"Development of risk prediction equations for incident chronic kidney disease","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/aje\/kws207","article-title":"Interpreting incremental value of markers added to risk prediction models","volume":"176","author":"Pencina","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"751","DOI":"10.7326\/0003-4819-149-10-200811180-00009","article-title":"Assessing the value of risk predictions by using risk stratification tables","volume":"149","author":"Janes","year":"2008","journal-title":"Ann Intern Med"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-150-11-200906020-00007","article-title":"Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures","volume":"150","author":"Cook","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"e0120443","DOI":"10.1371\/journal.pone.0120443","article-title":"External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.amjcard.2021.07.047","article-title":"Independent association of fatty liver index with left ventricular diastolic dysfunction in subjects without medication","volume":"158","author":"Furuhashi","year":"2021","journal-title":"Am J Cardiol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pathophys.2008.04.003","article-title":"Risk factors and mechanisms of non-alcoholic steatohepatitis","volume":"15","author":"Rivera","year":"2008","journal-title":"Pathophysiology"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2010.11.007","article-title":"Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?","volume":"54","author":"Targher","year":"2011","journal-title":"J Hepatol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","DOI":"10.1038\/s41581-021-00519-y","article-title":"Association of metabolic dysfunction-associated fatty liver disease with kidney disease","author":"Wang","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"e1001680","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/jdi.13735","article-title":"Circulating level of FABP4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals","volume":"13","author":"Tanaka","year":"2022","journal-title":"J Diabetes Investig"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nature05844","article-title":"Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2","volume":"447","author":"Furuhashi","year":"2007","journal-title":"Nature"},{"key":"2023030115325616200_","first-page":"2640","article-title":"Adipocyte\/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice","volume":"118","author":"Furuhashi","year":"2008","journal-title":"J Clin Invest"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5551\/jat.48710","article-title":"Fatty acid-binding protein 4 in cardiovascular and metabolic diseases","volume":"26","author":"Furuhashi","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000368412","article-title":"Ectopic expression of fatty acid-binding protein 4 in the glomerulus is associated with proteinuria and renal dysfunction","volume":"128","author":"Tanaka","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12882-020-02122-y","article-title":"Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria","volume":"21","author":"Tanaka","year":"2020","journal-title":"BMC Nephrol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41419-021-03850-1","article-title":"Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism","volume":"12","author":"Chen","year":"2021","journal-title":"Cell Death Dis"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"119023","DOI":"10.1016\/j.lfs.2021.119023","article-title":"Genetic inhibition of FABP4 attenuated endoplasmic reticulum stress and mitochondrial dysfunction in rhabdomyolysis-induced acute kidney injury","volume":"268","author":"Liu","year":"2021","journal-title":"Life Sci"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"566535","DOI":"10.3389\/fimmu.2020.566535","article-title":"Inhibition of fatty acid-binding protein 4 attenuated kidney fibrosis by mediating macrophage-to-myofibroblast transition","volume":"11","author":"Feng","year":"2020","journal-title":"Front Immunol"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"e115429","DOI":"10.1371\/journal.pone.0115429","article-title":"Urinary excretion of fatty acid-binding protein 4 is associated with albuminuria and renal dysfunction","volume":"9","author":"Okazaki","year":"2014","journal-title":"PLoS One"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"E827","DOI":"10.1152\/ajpendo.00378.2020","article-title":"New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity","volume":"319","author":"Furuhashi","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1253\/circj.CJ-18-0082","article-title":"Plasma xanthine oxidoreductase activity as a novel biomarker of metabolic disorders in a general population","volume":"82","author":"Furuhashi","year":"2018","journal-title":"Circ J"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jdi.12982","article-title":"Independent links between plasma xanthine oxidoreductase activity and levels of adipokines","volume":"10","author":"Furuhashi","year":"2019","journal-title":"J Diabetes Investig"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1038\/s41598-021-83494-5","article-title":"Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study","volume":"11","author":"Saito","year":"2021","journal-title":"Sci Rep"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000076640","article-title":"Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995\u20132000","volume":"47","author":"Tanaka","year":"2004","journal-title":"Intervirology"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324525","article-title":"Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale","volume":"54","author":"Tanaka","year":"2011","journal-title":"Intervirology"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"dju041","DOI":"10.1093\/jnci\/dju041","article-title":"Net risk reclassification P values: valid or misleading?","volume":"106","author":"Pepe","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2023030115325616200_","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/EDE.0000000000000018","article-title":"Net reclassification indices for evaluating risk prediction instruments: a critical review","volume":"25","author":"Kerr","year":"2014","journal-title":"Epidemiology"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac188\/44477535\/gfac188.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/3\/700\/49352574\/gfac188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/3\/700\/49352574\/gfac188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T01:07:36Z","timestamp":1700615256000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/3\/700\/6591613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,24]]},"published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac188","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2022,5,24]]}}}